<- Go Home
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Market Cap
$473.4M
Volume
1.9M
Cash and Equivalents
$8.2M
EBITDA
-$214.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$68.2M
Profit Margin
58.35%
52 Week High
$13.15
52 Week Low
$4.73
Dividend
N/A
Price / Book Value
37.83
Price / Earnings
-2.19
Price / Tangible Book Value
-341.02
Enterprise Value
$501.1M
Enterprise Value / EBITDA
-2.33
Operating Income
-$216.3M
Return on Equity
210.35%
Return on Assets
-48.02
Cash and Short Term Investments
$143.8M
Debt
$171.6M
Equity
$12.5M
Revenue
$116.9M
Unlevered FCF
-$113.0M
Sector
Biotechnology
Category
N/A